Literature DB >> 19571433

Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors.

Satomi Nagashima1, Makiko Shimizu, Hiroshi Yano, Norie Murayama, Toshio Kumai, Shinichi Kobayashi, F Peter Guengerich, Hiroshi Yamazaki.   

Abstract

Human flavin-containing monooxygenase 3 (FMO3)-mediated microsomal oxygenation activity, levels of FMO3 protein and FMO3 mRNA and modifications were investigated in Japanese livers genotyped for the FMO3 gene. Significant correlations were observed for benzydamine N-oxygenation or methyl p-tolyl sulfide S-oxygenation activity (in the range of approximately 20- to approximately 40-fold) and FMO3 levels determined immunochemically in liver microsomes (r(2)=0.73-0.75, p<0.0001, n=16). Preincubation with the reducing agent ascorbate revealed that FMO3 activity in some liver samples is suppressed. Microsomal FMO3 protein content (approximately 40-fold) was correlated with FMO3 mRNA levels (r(2)=0.55, p=0.0010, n=16), but FMO3 haplotypes did not affect FMO3 mRNA expression (approximately 100-fold) under the conditions used. FMO3 mRNA levels were multivariately correlated with trans-acting factors, i.e. hepatic nuclear factor 4 (HNF-4) mRNA and nuclear factor Y box-binding protein (NF-Y) mRNA (r(2)=0.31, p=0.0017, n=37). These results suggest that considerable individual differences in FMO3 levels may exist in Japanese livers. The liver-enriched transcription factor HNF-4 appears to be a determinant of FMO3 expression in livers, as well as the ubiquitous factor NF-Y.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19571433      PMCID: PMC4755719          DOI: 10.2133/dmpk.24.218

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  28 in total

1.  Cytochromes P450 and flavin monooxygenases--targets and sources of nitric oxide.

Authors:  E T Morgan; V Ullrich; A Daiber; P Schmidt; N Takaya; H Shoun; J C McGiff; A Oyekan; C J Hanke; W B Campbell; C S Park; J S Kang; H G Yi; Y N Cha; D Mansuy; J L Boucher
Journal:  Drug Metab Dispos       Date:  2001-11       Impact factor: 3.922

2.  Inter-individual variation of cytochrome P4502J2 expression and catalytic activities in liver microsomes from Japanese and Caucasian populations.

Authors:  H Yamazaki; A Okayama; N Imai; F P Guengerich; M Shimizu
Journal:  Xenobiotica       Date:  2006-12       Impact factor: 1.908

3.  Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression.

Authors:  Sevasti B Koukouritaki; Pippa Simpson; Catherine K Yeung; Allan E Rettie; Ronald N Hines
Journal:  Pediatr Res       Date:  2002-02       Impact factor: 3.756

Review 4.  Flavin mono-oxygenase (FMO)--the 'other' oxidase.

Authors:  S C Mitchell
Journal:  Curr Drug Metab       Date:  2008-05       Impact factor: 3.731

5.  Benzydamine N-oxygenation as a measure of flavin-containing monooxygenase activity.

Authors:  Catherine K Yeung; Allan E Rettie
Journal:  Methods Mol Biol       Date:  2006

6.  Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes.

Authors:  Souzan B Yanni; Pieter P Annaert; Patrick Augustijns; Arlene Bridges; Yan Gao; Daniel K Benjamin; Dhiren R Thakker
Journal:  Drug Metab Dispos       Date:  2008-03-24       Impact factor: 3.922

7.  Alternative processing events in human FMO genes.

Authors:  Virginie Lattard; Jun Zhang; John R Cashman
Journal:  Mol Pharmacol       Date:  2004-06       Impact factor: 4.436

8.  Genetic polymorphism of the flavin-containing monooxygenase 3 (FMO3) associated with trimethylaminuria (fish odor syndrome): observations from Japanese patients.

Authors:  Hiroshi Yamazaki; Makiko Shimizu
Journal:  Curr Drug Metab       Date:  2007-06       Impact factor: 3.731

9.  Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

Authors:  B J Ring; J Catlow; T J Lindsay; T Gillespie; L K Roskos; B J Cerimele; S P Swanson; M A Hamman; S A Wrighton
Journal:  J Pharmacol Exp Ther       Date:  1996-02       Impact factor: 4.030

10.  Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein beta (C/EBPbeta) liver inhibitory and liver activating proteins.

Authors:  David E Klick; Jeff D Shadley; Ronald N Hines
Journal:  Biochem Pharmacol       Date:  2008-05-07       Impact factor: 5.858

View more
  5 in total

Review 1.  Emerging roles of xenobiotic detoxification enzymes in metabolic diseases.

Authors:  Michael C Petriello; Jessie B Hoffman; Andrew J Morris; Bernhard Hennig
Journal:  Rev Environ Health       Date:  2017-03-01       Impact factor: 3.458

2.  Developmental variations in metabolic capacity of flavin-containing mono-oxygenase 3 in childhood.

Authors:  Makiko Shimizu; Travis Denton; Marie Kozono; John R Cashman; J Steven Leeder; Hiroshi Yamazaki
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 3.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

4.  Development of a Physiologically-Based Pharmacokinetic Model for Sirolimus: Predicting Bioavailability Based on Intestinal CYP3A Content.

Authors:  C Emoto; T Fukuda; S Cox; U Christians; A A Vinks
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-07-24

5.  Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.

Authors:  Yong-Jun Tang; Kai Hu; Wei-Hua Huang; Chong-Zhi Wang; Zhi Liu; Yao Chen; Dong-Sheng Ouyang; Zhi-Rong Tan; Hong-Hao Zhou; Chun-Su Yuan
Journal:  Biomed Res Int       Date:  2017-02-26       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.